As previously reported for HER2 targeting ADCs, there appears to be a difference in the rates of drug-induced pneumonitis in patients treated with Dato-DXd who have lung cancer compared to those who have other tumor types, such as breast cancer. This evidence concerns the gene ERBB2 and neoplasm.